10 July 2020
A generous gift of £3.5 million from Lakshmi Mittal and his family has secured the future of a critical professorship in vaccinology at the University. The post, which is currently held by Professor Adrian Hill, will be known as the Lakshmi Mittal and Family Professorship of Vaccinology in recognition of this support.
27 June 2020
Volunteers in Brazil have begun receiving a trial vaccine against COVID-19, in Latin America’s first phase 3 COVID-19 clinical trial. The trial officially began on Saturday 20th June and will enrol 5,000 volunteers across the country. Vaccinations will take place in Sao Paulo, Rio de Janeiro and a site in the Northeast of Brazil. The Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials on 2nd June, which are being conducted in partnership with AstraZeneca.
25 June 2020
The Duke paid a visit to the Oxford Vaccine Centre facility at the Churchill Hospital in Oxford where the vaccine has been developed and trials are now underway. During his visit, The Duke was briefed about the Group’s work by Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, who developed the vaccine and Professor Andrew Pollard, Professor of Paediatric Infection and Immunity at the University of Oxford, who is leading the clinical trial team.
17 June 2020
Prof Sarah Gilbert from the Jenner Institute is speaking at a video linked Global Covid-19 vaccine congress on Monday 21st June 2020 organised by the International Society for Vaccines. The congress is free to scientists with an interest in COVID‐19 vaccines (pre‐registration required).
5 June 2020
The University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).
4 June 2020
On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
3 June 2020
On April 30, the University of Oxford and AstraZeneca announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. A Phase I/II clinical trial of the Oxford vaccine began in April in the UK to assess safety and immune response in over 1,000 healthy volunteers aged 18 to 55 years across several trial centres in southern England. As the vaccine trials move to Phase III, a larger population is being enrolled consisting of 10,000 participants in the UK with AstraZeneca enrolling 30,000 particpants in the US. On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
2 June 2020
On 13 May Professor Sarah Gilbert gave a short talk and participated in an informal discussion with ambassadors of the United Nations member states, hosted by the UK mission. Here is a summary of her talk.
22 May 2020
University of Oxford researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers. The phase I trial in healthy adult volunteers began in April. More than 1,000 immunisations have been completed and follow-up is currently ongoing. The next study will enrol up to 10,260 adults and children and will involve a number of partner institutions across the country.
22 May 2020
The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers. This study aims to assess how well people across a broad range of ages could be protected from COVID-19 with this new vaccine called ChAdOx1 nCoV-19. It will also provide valuable information on safety aspects of the vaccine and its ability to generate good immune responses against the virus. Follow the title link to learn more.
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine
21 May 2020
AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s vaccine widely accessible around the world in an equitable manner. AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall. The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.
19 May 2020
We are writing in response to the article published on Forbes online on 16th May by William Haseltine relating to the BioRxiv preprint publication ‘ChAdOx1 nCoV-19 vaccination prevents SARSCoV-2 pneumonia in rhesus macaques' by van Doremalen et al (2020).
18 May 2020
The Government has announced £65.5 million of new funding for the vaccine being developed at the University of Oxford as coronavirus vaccine trials accelerate.
30 April 2020
A team from the Medical Sciences Division led by Dr Anita Milicic at the Jenner Institute has received a share of $14 million in funding from the Chan Zuckerberg Initiative as one of 29 projects that will explore emerging ideas regarding the role of inflammation in disease.
30 April 2020
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University. The vaccine candidate was developed by the University’s Jenner Institute who began trials in humans last week jointly with the University’s Oxford Vaccine Group.
16 April 2020
MilliporeSigma (also known as Merck KGaA, and distinct from the pharmaceutical company Merck & Co Inc / MSD) and the Jenner Institute today announced that the Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a critical step in quickly and safely delivering it from the lab to patients.
2 April 2020
Vaccine development during an epidemic: Experts have estimated that it will take 12-18 months to develop a new vaccine at high speed. Under normal circumstances, most vaccine development programmes take more than five years, so this is still a considerably accelerated timescale.
27 March 2020
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still. The team will enrol healthy volunteers aged between 18 – 55, who, if they pass screening, will be the first humans to test the new vaccine, called ChAdOx1 nCoV-19.
25 March 2020
During the developing COVID-19 pandemic, the Jenner Institute is taking measures to prevent the spread of the disease. Departments are instructed by the University’s Registrar to work from home and manage building closures. This is to restrict any contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions: Only essential activities should continue on site (e.g. research relating to Covid-19 or that of national importance, or the maintenance of research equipment and animal welfare). Departments are responsible for defining what is essential, in line with divisional guidance, and should provide appropriate operating procedures. The Pro-Vice Chancellor for Research will be in touch with Divisions to assist in drawing up guidance. Other research and teaching continues remotely where possible and students return home (if possible and where that has not already happened). Departments physically close except where essential activities have to be done on site. Staff work remotely where possible. Only core support functions and other essential activities continue on site and only with critical staff on site, e.g. building access and maintenance security, animal welfare, maintenance of research equipment.
20 March 2020
Researchers at Oxford University are working with great care, and due haste, in developing a new vaccine for coronavirus. Production is underway and trials could start in late Spring. If proven effective, a safe coronavirus vaccine could provide an exit strategy for the pandemic and save lives. While we understand the interest, we ask that the media do not continue to contact researchers while this critical work is underway so that they can focus on these efforts. We will issue press releases in due course.